- Home
- EVAX vs KPRX Comparison
EVAX vs KPRX Comparison
Compare EVAX & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- KPRX
- Stock Information
- Founded
- EVAX 2008
- KPRX 1998
- Country
- EVAX Denmark
- KPRX United States
- Employees
- EVAX N/A
- KPRX N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EVAX Health Care
- KPRX Health Care
- Exchange
- EVAX Nasdaq
- KPRX Nasdaq
- Market Cap
- EVAX 8.7M
- KPRX 10.0M
- IPO Year
- EVAX 2021
- KPRX N/A
- Fundamental
- Price
- EVAX $0.89
- KPRX $3.20
- Analyst Decision
- EVAX Strong Buy
- KPRX Strong Buy
- Analyst Count
- EVAX 2
- KPRX 1
- Target Price
- EVAX $11.00
- KPRX $10.00
- AVG Volume (30 Days)
- EVAX 82.5K
- KPRX 46.6K
- Earning Date
- EVAX 10-31-2024
- KPRX 11-08-2024
- Dividend Yield
- EVAX N/A
- KPRX N/A
- EPS Growth
- EVAX N/A
- KPRX N/A
- EPS
- EVAX N/A
- KPRX 1.69
- Revenue
- EVAX $3,295,000.00
- KPRX $16,020,000.00
- Revenue This Year
- EVAX $4,845.21
- KPRX N/A
- Revenue Next Year
- EVAX $30.30
- KPRX N/A
- P/E Ratio
- EVAX N/A
- KPRX $1.93
- Revenue Growth
- EVAX N/A
- KPRX N/A
- 52 Week Low
- EVAX $0.85
- KPRX $3.00
- 52 Week High
- EVAX $13.61
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- EVAX 21.83
- KPRX 42.05
- Support Level
- EVAX $0.85
- KPRX $3.08
- Resistance Level
- EVAX $0.96
- KPRX $4.04
- Average True Range (ATR)
- EVAX 0.15
- KPRX 0.28
- MACD
- EVAX -0.00
- KPRX -0.03
- Stochastic Oscillator
- EVAX 5.75
- KPRX 12.97
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.